Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002527 · ClinicalTrials.gov registry record · Phase 3
Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed
A Phase 3 study of Colorectal Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 635
- Enrollment target
- 20
- Study locations
NCT00002527: Completed Phase 3 study of Colorectal Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00002527 is a Phase 3 study of Colorectal Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 635 participants, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002527, a Phase 3 study of Colorectal Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 635 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of aspirin may be an effective way to prevent the recurrence of polyps in colorectal cancer. PURPOSE: Randomized phase III trial to study the effectiveness of aspirin in treating patients who have stage I, stage II, or stage III colorectal cancer that has been surgically removed.
Conditions Studied
Interventions
- OTHER placebo
- DRUG aspirin
Study Locations (20)
Iowa
- CCOP - Cedar Rapids Oncology Project - Cedar Rapids
- CCOP - Iowa Oncology Research Association - Des Moines
- University of Iowa Hospitals and Clinics - Iowa City
- Siouxland Hematology-Oncology - Sioux City
Illinois
- University of Chicago Cancer Research Center - Chicago
- CCOP - Illinois Oncology Research Association - Peoria
- CCOP - Carle Cancer Center - Urbana
Minnesota
- University of Minnesota Cancer Center - Minneapolis
- Mayo Clinic Cancer Center - Rochester
- CentraCare Clinic - Saint Cloud
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- University of Massachusetts Memorial Medical Center - Worcester
Missouri
- Ellis Fischel Cancer Center - Columbia - Columbia
- Barnes-Jewish Hospital - St Louis
Arizona
- CCOP - Scottsdale Oncology Program - Scottsdale
California
- UCSF Cancer Center and Cancer Research Institute - San Francisco
Florida
- CCOP - Mount Sinai Medical Center - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 635 participants |
| Start Date | 1993-05 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
What the finished NCT00002527 record still lists
NCT00002527 is an interventional study that assigns participants to a tested intervention. The registered 635 participants enrollment target is mid-sized for trials with a published cap, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00002527 names 20 study sites across 11 states, led by Iowa, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00002527 about?
NCT00002527 is a clinical study titled "Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of aspirin may be an effective way to prevent the recurrence of polyps in colorectal cancer. PURPOSE: Randomized phase III trial to study the effectiveness of aspirin in...
What is the current status of trial NCT00002527?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 635 participants. The study started on 1993-05. Estimated completion is 2006-01.
What conditions does trial NCT00002527 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT00002527?
The interventions under investigation include: placebo (OTHER), aspirin (DRUG).
Who is sponsoring clinical trial NCT00002527?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002527 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002527's enrollment target sits among peer trials
635 68th of 381 higher than 314 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
The Northern-European Initiative on Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
COMPLETED · Phase 3
-
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 3
-
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03478826 · 635 participants
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
- NCT03821129 · 636 participants · NA
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
- NCT00573027 · 634 participants · NA
Heart Disease of the Small Arteries in Women and Men
- NCT04108156 · 634 participants · Phase 3
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia